RemovedRisk Factors
contract period. We may experience cost overruns due to these factors resulting in losses or reduced profitability which could materially and adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
inability to secure new government contracts, contract modification or termination, criminal and civil penalties and fines, and loss of business opportunities, any of which could adversely affect impact our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Issues raised by the use of Artificial Intelligence (AI) and machine learning in our operations may subject us to new or heightened legal, regulatory, ethical or other concerns and result in liability or reputational harm. We have started to leverage AI in certain of our operations and implemented policies and controls to mitigate many of the novel risks presented by these new technologies. We face risks related to the incorporation of AI in our operations due to the challenges inherent with properly managing its use. There can be no assurance that our investments in AI will pay off. If our employees, customers or business partners do not comply, or are dissatisfied with, our policies and practices related to the use of such technologies we may experience legal, regulatory or reputational liability. Further, we need to continuously adapt to new laws and regulations such as the European Union's Artificial Intelligence (AI) Act, and others in the United States and other jurisdictions, regulating the use of these technologies, the impact and cost of which could be significant.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our operations, and the operations of our suppliers, distributors or customers, could be subject to natural and man made disasters as well as the impact of governmental actions and regulations in response to such events, any of which
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are subject to risks related to legal claims and proceedings filed by or against us, and adverse outcomes in these matters may materially harm our business. We are subject from time to time to various claims, disputes, investigations, demands, arbitration, litigation or other legal proceedings which may result in material damages, place restrictions on our business operations or divert our management's attention from other business issues and opportunities. Legal matters are
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
unpredictable and significant adverse judgments, penalties, settlement amounts or defense costs could materially and adversely affect our liquidity and capital resources. It is also possible that, as a result of a present or future governmental or other proceeding or settlement significant restrictions will be placed upon, or significant changes made to our business practices and operations. Any such restrictions or changes may adversely affect our profitability or increase our compliance costs. The unfavorable resolution of one or more of these matters could have a material and adverse impact on our business, results of operations and financial condition.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
The recent cuts in staff at the FDA's Center for Devices and Radiological Health may result in the FDA taking longer to review applications which could cause significant delays in regulatory approvals resulting in longer timelines to bring new medical devices to market for certain products in our Medical segment. We expect the effects of these uncertainties to impact our orders and sales in the near term, and adversely impact our business, results of operations and financial condition, although we are unable to predict the exact duration or magnitude of the impact.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
The actual revenue, cost and gross profit realized on from these contracts can vary, sometimes substantially, differ substantially from original projections due to a variety of factors including inaccurate costs estimation, inflation, currency fluctuations, errors in specifications or designs, other unanticipated design error, technical problems with our products or services which require that we remedy the problem at our cost, problems, supplier failures, regulatory delays, customer difficulty in obtaining required governmental permits or approvals or other customer-caused delays, issues, changes in regulations and laws, construction delays of new NPPs and decommissioning of existing NPPs, delays, limited history with new products and customers, contract termination, or other unanticipated circumstances over the circumstances.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur significant face costly legal expenses defending against such allegations disputes and could be subject to significant damages, enjoined from the sale of our products that contained the open source software and required to comply with the foregoing conditions, which could disrupt the distribution and sale of some of our products and adversely affect our business, results of operations and financial condition. software.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the nuclear liability and indemnification authority in the United States this protection is reduced or other countries is eliminated or adversely modified in the future, our business removed it could be materially and adversely affected if lead the owners and operators of NPPs cancel or delay plans to build new plants or curtail the operations of existing plants. plants, materially and adversely affecting our business.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any reduction in the resources or government funding of our customers, including funding, such as a result of a government shutdown, the U.S. government's failure to raise the debt ceiling, or other governmental action or order to reduce governmental budgets and spending generally, including in non-U.S. countries, general budget cuts could reduce our sales and impede our ability to generate revenue.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
International tariffs, including Our operating results may be impacted by the effects of, and changes in, worldwide economic conditions, international trade, tariffs that affect our products or components within our products, and retaliatory countermeasures, export controls and other trade barriers or barriers, global trade wars or domestic preferences which could increase our costs and materially and adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our supply chains could also be disrupted by factors such as supplier Suppliers capacity constraints, operational or quality issues, bankruptcy bankruptcies or exiting of the other business for other reasons, terminations, decreased availability of key materials, and external events like natural disasters, pandemics, war, terrorism, tariffs wars and other governmental actions. actions can make it difficult to find replacements quickly or at similar costs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Many governments, Governments, regulators, investors, employees, customers, and other stakeholders are increasingly focused placing emphasis on the environmental, social and governance performance of companies, including their focus on climate change, greenhouse gas emissions, human and civil rights, diversity, equity and inclusion initiatives, companies with diverging varying and sometimes polar opposite goals and objectives. conflicting expectations.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
We operate in an industry where the risks associated with related to radioactive materials and the public perception of views on nuclear energy could materially and adversely affect the our markets in which we operate and increase regulatory requirements and costs that could in turn materially costs, negatively impacting our business, results of operations and adversely affect our business. financial condition.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our failure to comply with any Non-compliance or improper handling of these on-going obligations could radioactive materials can result in the revocation of the applicable license, license revocation, which could result in the cancellation or delay of purchases by our customers. customers, penalties, fines and liability for accidents or contamination.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, certain of our some confidential information, information and customer data, may be data is gathered, processed, and stored on by third-party networks of vendors or service providers whom whose security and protection policies and procedures we have engaged. ultimately do not, and are unable to, control.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our business operations are subject to The Company operates under extensive regulation by various federal, state, and local governmental agencies in the United States and other countries in which we conduct business. business covering areas such as radioactive materials, antitrust, environmental, health and safety, food and drug, medical device, import/export, and labor laws.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Advertising and promotion of our products is closely monitored by the FDA requires that device and Federal Trade Commission to prevent false or misleading claims and manufacturers determine if must assess whether product modifications to approved products require new approvals, though the FDA can review these decisions.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
These additional expenses will could place pressure on profit margins or require us to increase the price of our products and services potentially affecting demand and, consequently, our business, results of operations and financial condition.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
(2)Pre-tax non-operating expenses of $23.0 million for the year ended December 31, 2025, include $15.7 million of mergers and acquisitions costs associated with our acquisitions of Paragon and Certrec; $2.9 million of restructuring and other related costs; $1.9 million of consulting costs related to Nuclear & Safety segment enterprise resource planning implementations which were substantially completed as of December 31, 2025; $1.3 million of one-time consulting fees related to IT services sourcing excellence; and a $1.0 million asset impairment of an equity investment (100% impairment).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On May 23, 2025, the Company completed a private offering of $400.0 million aggregate principal amount of 0.25% Convertible Senior Notes due 2030 (the “2030 Notes”), which included the initial purchasers' exercise in full of their option to purchase additional 2030 Notes. The Notes have a maturity date of June 1, 2030. Refer to discussion included within Liquidity and Capital Resources for more details.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On July 31, 2025, Mirion acquired 100% of the equity interest of Certrec for $82.9 million of purchase consideration ($80.6 million net of cash), subject to final closing statement balances. As part of the Nuclear & Safety segment, Certrec is a leading supplier of regulatory compliance and digital integration solutions for the energy industry. Mirion management believes the Certrec business will be pivotal in expanding our offerings in the nuclear power market and further strengthen the development of our digital ecosystem.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
September 2025 Class A Common Stock Offering, September 2025 Convertible Notes Offering, and Agreement to Purchase Paragon Energy Solutions
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On September 30, 2025, the Company completed a public offering of 19,906,322 shares of Mirion's Class A common stock at a public offering price of $21.35 per share, including the underwriters' exercise in full of their option to purchase additional shares. Additionally, on September 30, 2025, the Company completed a private offering of $375.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2031, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2031 Notes” and, together with the 2030 Notes, the “Convertible Notes). The Notes have a maturity date of October 1, 2031. The Company used the net proceeds from the Class A common stock offering, together with the net proceeds from the offering of 2031 Notes, to fund the acquisition of all of the outstanding membership interests of WCI-Gigawatt Intermediate Holdco, LLC, as the indirect parent of Paragon Energy Solutions, LLC, for approximately $585.0 million pursuant to the equity purchase agreement signed September 24, 2025. Remaining funds from the offerings will be used for general corporate purposes and working capital. Refer to discussion included within Liquidity and Capital Resources for more details.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On December 1, 2025, Mirion acquired 100% of the outstanding membership interest of WCI-Gigawatt Intermediate Holdco, LLC, the indirect parent of Paragon Energy Solutions, LLC (“Paragon”) for $588.4 million of gross purchase consideration ($581.3 million, net of cash and net working capital adjustment), subject to final closing statement balances. As part of the Nuclear & Safety segment, Paragon is a leading provider of highly engineered solutions for large-scale nuclear power plants and small modular reactors (SMRs) in the United States. Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs. Additionally, the addition of Paragon significantly enhances our presence in the U.S. nuclear power market and the developing SMR commercial entrants.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On June 5, 2025, the Company entered into Amendment No. 5 to the 2021 Credit Agreement ("Amendment No. 5"). Under Amendment No. 5, the Company utilized funds from the private offering of Convertible Senior Notes due 2030 completed on May 23, 2025 (see Note 9, Convertible Debt) to repay $244.6 million in outstanding principal and $8.3 million in accrued interest as well as to extend the maturity date of the term loan to June 5, 2032 (collectively, the "June 2025 Refinancing"). The June 2025 Refinancing was accounted for as a partial extinguishment and partial modification of the term loan debt. The Company accounted for $244.6 million of the term loan principal as an extinguishment of debt; the remaining $450.0 million of principal was accounted for as a modification to the extent the principal holdings at the syndicated lender level remained unchanged. As a result, the Company recorded a loss on partial debt extinguishment of $5.8 million within the Consolidated Statement of Operations for the period ended December 31, 2025 attributed to the derecognition of a proportionate amount of unamortized deferred financing costs.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Revolving Line of Credit - The revolving line of credit arrangement initially had a five year term (expiring October 2026) and bore interest at the greater of LIBOR (through June 30, 2023) / SOFR (subsequent to June 2023) or 0%, plus 2.25%. The terms of the revolving line of credit were amended on March 21, 2025, through Amendment No. 4 to the 2021 Credit Agreement ("Amendment No. 4"). Under Amendment No. 4, revolving credit commitments from lenders increased from $90.0 million to $175.0 million, and the maturity date extended to March 21, 2030, subject to a "springing" maturity date that is 91 days prior to the maturity date of the outstanding term loan under the 2021 Credit Agreement (but only to the extent the outstanding principal amount of the term loan exceeds $100.0 million on the date of determination, and a final statement maturity date that is early than 91 days after March 21, 2030).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
On May 23, 2025, the Company completed a private offering of $400.0 million in aggregate principal amount of 0.25% Convertible Senior Notes due 2030, including the initial purchasers’ exercise in full of their option to purchase additional Notes (the “2030 Notes”). The 2030 Notes were issued pursuant to an indenture, dated May 23, 2025 (the “May
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
Indenture”). The May Indenture includes customary covenants and sets forth certain events of default after which the 2030 Notes may be declared immediately due and payable and sets forth certain types of bankruptcy or insolvency events of default involving the Company after which the outstanding principal and accrued interest of the 2030 Notes becomes automatically due and payable.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The 2030 Notes will mature on June 1, 2030, unless earlier converted, redeemed or repurchased. The 2030 Notes will bear interest from May 23, 2025 at a rate of 0.25% per year payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2025. The 2030 Notes will be convertible at the option of the holders in certain circumstances discussed below. The 2030 Notes will be convertible into cash, shares of Mirion’s Class A common stock or a combination of cash and shares of Mirion’s Class A common stock, at the Company’s election.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
AddedMD&A
The initial conversion rate is 43.2751 shares of Mirion’s Class A common stock per $1,000 principal amount of 2030 Notes, which is equivalent to an initial conversion price of approximately $23.11 per share of Mirion's Class A common stock. The initial conversion price of the 2030 Notes represents a conversion premium of 32.5% to the last reported sale price of Mirion’s Class A common stock of $17.44 per share on May 20, 2025. The conversion rate is subject to adjustment under certain circumstances in accordance with the terms of the May Indenture.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RemovedMD&A
(In millions) Year Ended December 31, 2024 Year Ended December 31, 2023 Year Ended December 31, 2022 Net loss $ (36.6) $ (98.7) $ (288.4) Interest expense, net 51.3 57.1 41.9 Income tax provision (benefit) 2.7 (6.6) (18.2) Amortization 118.5 131.3 145.8 EBITA $ 135.9 $ 83.1 $ (118.9) Depreciation 31.9 31.5 28.7 EBITDA $ 167.8 $ 114.6 $ (90.2) Stock-based compensation expense 15.6 21.9 31.8 Increase (decrease) in fair value of warrant liabilities 5.3 24.8 (37.6) Goodwill impairment — — 211.8 Other impairments(1) — — 7.0 Loss on debt extinguishment — 2.6 — Foreign currency loss (gain), net 2.2 (0.3) 4.9 Cost of revenues impact from inventory valuation purchase accounting — — 6.3 Non-operating expenses(2)(3)(4)(5) 12.7 17.1 30.7 Adjusted EBITDA $ 203.6 $ 180.7 $ 164.7
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1)Other impairments for the year ended December 31, 2022 consist of $7.0 million of impairment charges primarily related to a business held for sale and an equity investment.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, 2022 (In millions) Medical Nuclear & Safety Corporate & Other Consolidated Income from operations $ (98.9) $ (103.1) $ (95.8) $ (297.8) Amortization 64.3 81.5 — 145.8 Depreciation 18.1 9.6 1.0 28.7 Cost of revenues impact from inventory valuation purchase accounting 0.9 5.4 — 6.3 Stock-based compensation 0.6 1.0 30.2 31.8 Goodwill impairment 87.3 124.5 — 211.8 Other impairments — 2.5 4.5 7.0 Non-operating expenses 14.6 2.6 13.8 31.0 Other income / expense — — 0.1 0.1 Adjusted EBITDA $ 86.9 $ 124.0 $ (46.2) $ 164.7
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In April 2023, one of our Russian customers made a claim against the Company, including liquidated damages for certain delays under the terms of an active project, in the amount of $19.3 million, and sent an updated claim statement in October 2023 totaling $21 million ($18 million of which accrue daily penalties), subject to a $14 million contractual cap (all amounts converted from Euros to U.S. Dollars). In November 2024, the Company reached an agreement to modify the underlying contract and the claim was rescinded by the customer. The modification was accounted for under ASC 606 Revenue Recognition which resulted in an immaterial impact to the Consolidated Statement of Operations for the fiscal year ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
In June 2023, the same Russian customer made a demand against the Company for the return of all payments received by the Company (totaling $10.2 million) related to a Finland nuclear power plant project cancelled in May 2022. In September 2024, the Company entered into a settlement agreement with the customer agreeing to refund €4.4 million to the customer. The amount is included in Accrued expenses and other current liabilities in the Consolidated Balance Sheet as of December 31, 2024, and the settlement resulted in an immaterial impact to the Consolidated Statement of Operations for the twelve months ended December 31, 2024.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Global interest rates remained elevated during 2024 after the series of U.S. federal funds interest rate increases that have occurred since late 2022, with slight decreases since late 2023. The Company's 2021 Credit Agreement provides for an $830.0 million senior secured first lien term loan facility (maturing in October 2028) and a $90.0 million senior secured revolving facility (expiring and maturing in October 2026) (collectively, the “Credit Facilities”).
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On April 3, 2023, the Company closed the sale of the Biodex Rehabilitation ("Rehab") business to Salona Global Medical Device Corporation ("Salona"). As a result, Rehab operating results are included in Mirion's operating results for the three months ended March 31, 2023.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Subsequent to the closing and during the fiscal year ended December 31, 2023, significant events occurred that negatively impacted the Company's ability to collect the remaining $7.0 million of cash payments owed for the sale, including disclosure by Salona that substantial doubt existed as to its ability to continue as a going concern. The Company elected to apply ASC 450 Contingencies to determine the loss on the business disposal since remaining payments were contingent on Salona's financial situation. As a result a loss on sale of business of $6.5 million was recorded in the Consolidated Statement of Operations during the year ended December 31, 2023.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
During the fiscal year ended December 31, 2024, Salona paid $1.2 million of the amount owed for the sale, and accordingly the Company recorded the payment as a reversal of the contingent loss in the Consolidated Statements of
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Operations. Doubt still exists regarding Salona's ability to pay the remaining amounts owed, and the Company will continue to monitor the situation.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On November 1, 2023, the Company acquired ec2 Software Solutions LLC and NUMA LLC (collectively “ec2”) for $33 million of cash consideration. Headquartered in Somerset, NJ, ec2 is a medical software company that designs, implements, and supports comprehensive software solutions servicing the nuclear medicine industry. The ec2 team and portfolio of solutions were integrated as part of the Company's Medical segment. As a result, ec2 operating results are included in Mirion's operating results for the full twelve months ended December 31, 2024, but are only included for the final two months in fiscal year 2023.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
On April 18, 2024, the Company announced that it would redeem all Public Warrants that remained outstanding at 5:00 pm New York City time on Monday, May 20, 2024 (the "Redemption Date"). Holders had the option to exercise their warrants and receive the Company's Class A common stock (i) in exchange for a payment in cash of the $11.50 per warrant exercise price, or (ii) on a “cashless” basis in which the exercising holder received a number of shares of the Company's Class A common stock determined under the warrant agreement based on the redemption date and the redemption fair market value. The “fair market value” was based on the average last price per share of the Company's Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the Notice of Redemption was sent. Substantially all holders elected a cashless exercise in their redemption elections. In addition, on June 4, 2024, the Company entered into a warrant exchange agreement with GS Sponsor II LLC to issue an aggregate of 1,768,000 shares of the Company’s Class A common stock upon the exchange of 8,500,000 Private Placement Warrants.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
The overall decrease increase in net loss income is primarily driven by increased revenues in both Medical and Nuclear & Safety and Medical segments, decreased amortization expense interest expense, a $17.4 million unrealized foreign currency gain as a result of fluctuations in the current year, lower selling, general and administrative costs associated with reduced
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash used in investing activities was $694.6 million for the year ended December 31, 2025 as compared to net cash used of $43.7 million for the year ended December 31, 2024 as compared to net cash used of $64.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Nuclear & Safety Medical segment revenues increased $44.7 $11.1 million for the year ended December 31, 2024 2025 compared with the year ended December 31, 2023 2024 primarily due to price increases increases, recovery from operational delays in the comparable prior period, foreign exchange fluctuations, and organic volume growth, partially offset by projects execution timing. growth.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
On a segment basis, income from operations in the Medical Nuclear & Safety segment was $101.1 million and $78.9 million for the year ended December 31, 2023 was $13.0 million 2025 and loss from operations for the year ended December 31, 2022 was $98.9 million, 2024, respectively, representing an increase of $111.9 $22.2 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Income from operations was $46.9 million for the year ended December 31, 2025 and loss from operations was $22.3 million for the year ended December 31, 2024 and loss from operations was $13.0 million for the year ended December 31, 2023, 2024, respectively, representing an increase in income from operations of $9.3 $24.6 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in income from operations period over period was largely due to the increased revenues noted previously, improved margin mix, a reduction in amortization expense of $7.3 million, lower bonus expenses restructuring and related impairment costs of $3.3 $3.4 million, and a net impact from the ec2 business lower compensation costs of $1.9 $1.6 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
As such, we entered into an interest rate swap (notional amount of $75.0 million) during the year ended December 31, 2024, 2023, as well as an additional interest rate swap (notional amount of $100.0 million) during the year ended December 31, 2025 to mitigate the risk of adverse changes in benchmark interest rates on the Company's future interest payments. payments (collectively, the "interest rate swaps").
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Research and development (“R&D”) expenses were $38.9 million for the year ended December 31, 2025 and $35.0 million for the year ended December 31, 2024 and $31.7 million for the year ended December 31, 2023, 2024, resulting in a an increase of $3.3 $3.9 million.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
We recorded a gain of $17.4 million for the year ended December 31, 2025 and a loss of $2.2 million for the year ended December 31, 2024 and a gain of $0.3 million for the year ended December 31, 2023 from foreign currency exchange.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Income from operations was $101.1 million for the year ended December 31, 2025 and $78.9 million for the year ended December 31, 2024 and loss from operations was $46.0 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
Partially offsetting the increase in Medical segment revenues period over period were reduced revenues from China and Russia orders compared to the prior year and reduced revenues from the disposal of the Rehab business in the prior year (see Note 2, Business Combinations, Acquisitions, and Business Disposals, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
RewordedMD&A
For more discussion of on the hedges of net investments, Company's debt profile, see Note 17, Fair Value Measurement, 8, Borrowings, and Note 18, Derivatives and Hedging, 9, Convertible Debt, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The Amendment No. 3 reduced the applicable margin rate on the term loans from 2.75% to 2.25% and reduced the credit spread based upon rate term to 0%, with other terms and conditions remaining consistent (effectively the existing loan was refinanced).
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The Amendment No. 3 was accounted for prospectively as a debt modification in accordance with ASC 470-50, Debt—Modifications and Extinguishments.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new
Quiet changesMD&A
The Amendment No. 6 was accounted for prospectively as a debt modification in accordance with ASC 470-50, Debt—Modifications and Extinguishments.
Read it in 10-K Feb 19, 2026 at sec.govopen_in_new